Health Ministry Proposes Separate Licensing Framework for Wholesale of Bulk Drugs

Date:

The Union Ministry of Health and Family Welfare has proposed amendments to the Drugs Rules, 1945, to introduce a separate licensing framework for the wholesale distribution of bulk drugs, including active and inactive pharmaceutical substances.

The proposed changes, outlined in Draft Gazette Notification G.S.R. No. 987 (E), dated November 2, 2026, aim to strengthen regulatory oversight and accountability across India’s pharmaceutical supply chain.

Under the proposed amendments, bulk drug wholesalers will have to apply through a separate application form, Form 19-BC, and obtain a dedicated licence under Form 20-BC.

Currently, a common licence covers wholesale distribution of both pharmaceutical formulations and bulk drugs. The proposed framework seeks to establish distinct licensing provisions for bulk drug operations.

The proposal was approved by the Drugs Consultative Committee (DCC) at its 67th meeting on November 17, 2025, and by the Drugs Technical Advisory Board (DTAB) at its 93rd meeting on February 16, 2026.

Under the proposed framework, licences will specify the categories of bulk drugs handled by wholesalers, including substances regulated under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985.

The wholesale sale of bulk drugs will also have to take place under the personal supervision of a competent person.

According to the ministry, the changes are intended to strengthen regulatory control, improve enforcement related to antimicrobial resistance and monitor the movement of drugs covered under the NDPS Act.

The proposed amendments provide a transition period for existing licence holders to comply with the revised requirements.

The new provisions will become applicable to existing licensees upon the expiry of their current licence retention period or 12 months after the final publication of the amendment, whichever is later.

The Health Ministry has invited objections and suggestions from stakeholders and members of the public within 30 days from the date copies of the Gazette notification containing the draft rules are made available.

Submissions can be sent to the Under Secretary (Drugs), Ministry of Health and Family Welfare, Government of India, U-6, Work Hall, C Wing, First Floor, Kartavya Bhawan-1, New Delhi–110001.

Stakeholders can also submit their responses through email at drugsdiv-mohfw@gov.in.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

spot_img

Popular

More like this
Related

First Batch of Students from IIT Delhi’s Abu Dhabi Campus Graduates

In a significant milestone for India's international presence in...

Strategic Defence Cooperation Between India and Japan Expanded, Missile and Maritime Technologies in Focus

India and Japan have agreed to accelerate cooperation in...

PM Modi’s Big Message to Indian Industry: Invest in India, Reduce Imports and Capture Global Markets

Prime Minister Narendra Modi inaugurated the Annual General Meeting...

Dr Jitendra Singh Unveils IISF 2026; Pune to Host 12th India International Science Festival from December 19

Union Minister of State (Independent Charge) for Science &...